|Title:||Sulfonamide inhibitors of aspartyl protease|
|Abstract:||The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.|
|Inventor(s):||Tung; Roger D. (Arlington, MA), Murcko; Mark A. (Holliston, MA), Bhisetti; Govinda R. (Lexington, MA)|
|Assignee:||Vertex Pharmaceuticals, Incorporated (Cambridge, MA)|
Patent Claim Types:|
see list of patent claims
|PCT Filed||September 07, 1993||PCT Application Number:||PCT/US93/08458|
|PCT Publication Date:||March 17, 1994||PCT Publication Number:||WO94/05639|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|African Regional IP Organization (ARIPO)||390||► subscribe|
|African Regional IP Organization (ARIPO)||9300572||► subscribe|
|African Regional IP Organization (ARIPO)||950||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.